Theravance Biopharma, Inc. (TBPH) Given Average Recommendation of “Hold” by Brokerages
Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned a consensus recommendation of “Hold” from the nine brokerages that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $41.33.
A number of analysts have issued reports on the company. Zacks Investment Research raised Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, September 5th. ValuEngine downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Robert W. Baird reaffirmed a “sell” rating and set a $22.00 price target on shares of Theravance Biopharma in a report on Wednesday, November 1st. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the stock a “buy” rating in a report on Wednesday, October 25th. Finally, BidaskClub downgraded Theravance Biopharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd.
In other Theravance Biopharma news, EVP Bradford J. Shafer sold 14,670 shares of Theravance Biopharma stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the sale, the executive vice president now directly owns 134,327 shares of the company’s stock, valued at approximately $4,133,241.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.10% of the stock is owned by insiders.
Theravance Biopharma (NASDAQ:TBPH) opened at $28.45 on Friday. Theravance Biopharma has a fifty-two week low of $23.15 and a fifty-two week high of $43.44. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.